The Hopkins Lupus Cohort is a unique 25 year, 2000 SLE patient longitudinal cohort in which patients are followed by protocol every 3 months, allowing study of time-varying (lupus activity, cardiovascular risk factors and, treatment) variables: 1) In the last RO-1 we successfully developed and published computed tomography angiography (CTA) for detection of non-calcified plaque in SLE and showed that it was associated with same day measures of SLE activity. In this RO-1, we will determine predictors of non-calcified plaque changes over time. We will bring an automated measure of non-calcified and calcified plaque burden to the clinic. 2) In the last RO-1 we successfully developed a consortium of U.S. sites interested in urine biomarkers of lupus nephritis activity, and discovered and published new biomarkers including urinary VCAM-1. In this RO-1 we have enlarged the consortium, arranged collaboration with the Glaxo Smith Kline belimumab lupus nephritis clinical trial to obtain longitudinal samples, and have begun our own urinary proteomics discovery program. We have already successfully brought urinary TWEAK to clinical trial stage, and anticipate bringing a panel of urinary biomarkers to the clinic for identification of lupus nephrits activity and prediction of treatment outcome. 3) In a past collaboration with Biogen Idec we found that BAFF and neutrophil gene signatures associate with same day SLE activity and predict activity over the next year. In this RO-1, we will continue that collaboration and determine whether these gene signatures are invariant in an individual or whether they change over time. If they change, we will evaluate the contributions of treatments and other variables. These investigations will demonstrate the utility of these signatures in indicating and predicting disease activity over time, so that they can be used in the clinic and in clinical trials.

Public Health Relevance

The Hopkins Lupus Cohort is a longitudinal study of over 2,000 SLE patients followed every 3 months by protocol. This RO-1 explores three new outcomes: 1) predicting how a measure of coronary artery atherosclerosis, non-calcified plaque, changes over time;2) tracking renal activity through urine biomarkers and 3) determining how gene signatures contribute to disease activity and organ damage.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
2R01AR043727-15A1
Application #
8755827
Study Section
Neurological, Aging and Musculoskeletal Epidemiology (NAME)
Program Officer
Witter, James
Project Start
1996-09-30
Project End
2016-07-31
Budget Start
2014-08-26
Budget End
2015-07-31
Support Year
15
Fiscal Year
2014
Total Cost
$682,380
Indirect Cost
$222,770
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Barber, Megan R W; Hanly, John G; Su, Li et al. (2018) Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken) 70:1294-1302
Davidson, Julie E; Fu, Qinggong; Rao, Sapna et al. (2018) Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort. Lupus Sci Med 5:e000237
Petri, Michelle; Magder, Laurence S (2018) Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. Arthritis Rheumatol 70:1790-1795
Choi, May Y; Clarke, Ann E; St Pierre, Yvan et al. (2018) Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care Res (Hoboken) :
Hardt, Uta; Larsson, Anders; Gunnarsson, Iva et al. (2018) Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. Arthritis Res Ther 20:36
Pejchinovski, M; Siwy, J; Mullen, W et al. (2018) Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. Lupus 27:6-16
Little, Jayne; Parker, Ben; Lunt, Mark et al. (2018) Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford) 57:677-687
Iftikhar, Mustafa; Kaur, Ramandeep; Nefalar, April et al. (2018) MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. Retina :
Merrill, Joan T; Petri, Michelle A; Buyon, Jill et al. (2018) Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Sci Med 5:e000263
Eudy, Amanda M; Siega-Riz, Anna Maria; Engel, Stephanie M et al. (2018) Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis 77:855-860

Showing the most recent 10 out of 220 publications